Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer

NCT06595563 is registered in ClinicalTrials.gov with Jules Bordet Institute as lead sponsor.

NCT NCT06595563
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06595563 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer
Lead sponsor
Jules Bordet Institute
Phase
Phase 2
Overall status
Terminated
Start date
June 30, 2026
Completion date
July 23, 2026
Enrollment
87 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

her2-positive advanced breast cancer, her2-positive metastatic breast cancer